Gretchen Belzer Curl, MD
Family Medicine · Mandan, NDNPI 1699878405
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 172 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $582 and has fallen 65.6% since, to $201 in 2025. Among family medicine clinicians in ND with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $16.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$463
- Astellas Pharma US Inc$441
- Amgen$300
- Lilly USA, LLC$269
- Pfizer$242
- Novo Nordisk$181
- plus $862 from 19 others
What the payments were for
- Food & beverage$2,65796%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 32 | $463 |
| Astellas Pharma US Inc | 23 | $441 |
| Amgen | 20 | $300 |
| Lilly USA, LLC | 27 | $269 |
| Pfizer | 16 | $242 |
| Novo Nordisk | 6 | $181 |
| Boehringer Ingelheim | 10 | $155 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $104 |
| Merck | 5 | $77 |
| Corcept Therapeutics | 1 | $75 |
| Novartis | 5 | $71 |
| AstraZeneca | 4 | $67 |
| E.r. Squibb & Sons, L.L.C. | 3 | $58 |
| Johnson & Johnson | 3 | $41 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Madrigal Pharmaceuticals | 1 | $23 |
| Phadia US Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Bayer | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $6 |
How this compares
$2,757 in reported general payments places this provider in the 90th percentile of 337 family medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 52 | $40,572 |
| OzempicSemaglutide | 42 | $38,965 |
| TrulicityDulaglutide | 25 | $22,386 |
| MounjaroTirzepatide | 12 | $11,833 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $9,176 |
| MyrbetriqMirabegron | 18 | $8,285 |
| Paliperidone ErPaliperidone | 12 | $6,083 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 20 | $5,792 |
| Levothyroxine Sodium | 363 | $5,471 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,131 |
| VascepaIcosapent Ethyl | 13 | $4,593 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $4,401 |
| Tiotropium Bromide | 11 | $4,263 |
| Duloxetine Hcl | 106 | $3,302 |
| Atorvastatin Calcium | 315 | $3,020 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $155 | $45,70363 claims |
| Novo NordiskOzempic | $181 | $38,96542 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $269 | $34,21937 claims |
| MerckJanumet Xr | $77 | $9,17612 claims |
| Astellas Pharma US IncMyrbetriq | $441 | $8,28518 claims |
| PfizerAbrysvo | $242 | $5,79220 claims |
| AbbVieSynthroid | $463 | $2,97952 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 337 family medicine providers in North Dakota.
Other family medicine in Mandan
- Thomas ThorsonMandan$241K
- Anthony JohnsonMandan$7K
- Dale KleinMandan$3K
- Meghan HendricksonMandan$3K
- Sadaf YousufMandan$1K
- Andrew DockterMandan$983
- Richard VetterWest Fargo$294K
- Gregory GreekGrand Forks$216K
- Katherine NeubauerWest Fargo$160K
- Spencer BerryFargo$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.